RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311
BeiGene Is Maintained at Buy by Guggenheim
BeiGene Price Target Raised to $350.00/Share From $348.00 by Guggenheim
BeiGene Analyst Ratings
RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating
BeiGene's Strong Market Position and Promising Financial Outlook Drive Buy Rating
TD Cowen Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $334
BeiGene's Strong Market Position and Growth Potential Affirmed by Buy Rating
BeiGene Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), BeiGene (ONC) and BioNTech SE (BNTX)
TD Cowen Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $334
BeiGene Price Target Maintained With a $334.00/Share by TD Securities
BeiGene (ONC) Receives a Buy From TD Cowen
BeiGene Analyst Ratings
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $317
BeiGene Analyst Ratings
Guggenheim Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $348
RBC Capital Initiates BeiGene(ONC.US) With Buy Rating, Announces Target Price $312
BeiGene Analyst Ratings
RBC Initiates BeiGene at Outperform With $312 Price Target